Condition
Glucagon
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Completed2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07350512Not ApplicableNot Yet Recruiting
Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants
NCT06921824Not ApplicableCompleted
Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants
NCT07141472Not ApplicableCompleted
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
Showing all 3 trials